More Stories

Informist, Friday, Nov. 21, 2025

 

MUMBAI – The Nifty Pharma index is expected to move in range with a negative bias next week as the index reached its highest levels since July due to which investors are likely to book profits in the upcoming trading sessions, according to technical analysts. Weakness in the market is seen despite the overall performance of the pharmaceutical companies was better than expected in the September quarter. 

 

The Nifty pharma index touched an over three-month high of 22888 points on Monday but gave up gains and ended 0.5% lower at 22695.15 points on Friday. The index is likely to move find support around 22200 points and face resistance around 22950 points, according to Anshul Jain, technical analyst at Laxmishree Investments and Securities. Among the constituents in the Nifty Pharma index, JB Chemicals and Pharmaceuticals declined over 5% and Torrent Pharmaceuticals fell nearly 4%, for the week ended Friday. Only two stocks in the index ended in green during the week with Sun Pharmaceuticals and Abbott India rising around 1?ch. 

 

In other news, the pharmaceutical industry is poised to play a critical role in driving economic growth of the country as per a report by EY Parthenon and Organisation of Pharmaceutical Producers of India. The report said that growth in India's pharmaceutical industry will be driven by dominance in generics and vaccines, the advancing contract research, development, and manufacturing organisation, contract development and manufacturing organisation sector, and the expansion of Global Capability Centers. 

 

The report said that the pharmaceutical exports have surged from $15.07 billion in 2013-14 to $27.85 billion in FY24, with projections to exceed $30 billion soon. 

 

TOP HEADLINES

* SC rejects tax department's plea to reopen assessment of Lupin's income
* Alkem Lab launches De Simone probiotic formulation in India
* Income-tax tribunal quashes INR 594 mln of INR 1.1-bln demand against Dabur
* Eris Life board to meet Mon, mull preferential issue of equity shares
* Biocon arm gets US FDA approval for tofacitinib extended release tablets
* Glenmark Pharma gets European Commission nod to market Winlevi
* AstraZeneca, Sun Pharma enter brand partnership to market hyperkalaemia drug
* HC refuses to bar Natco Pharma from selling insecticide on FMC Corp plea
* Analyst Concall: Max Health says settled tariff dispute with insurance cos
* Analyst Concall:Glenmark Pharma sees FY27 revenue at INR 170 bln-INR 180 bln
* US FDA ends inspection at Lupin's Nagpur unit with no observation
* Alembic Pharma gets US FDA OK for new drug Diltiazem Hydrochloride
* Earnings Review: Max Health consol PAT rises sharply in Q2 on tax write-back
* Earnings Review: One-off revenue lifts Glenmark Pharma Q2 PAT, sales
* Caplin Point arm Triwin Pharma acquires land in Mexico to set up mfg unit
* US FDA ends inspection at Dr Reddy's Andhra unit with zero observations
* Aurobindo Pharma arm's Rajasthan unit gets nine observations from US FDA
* Divi's Lab says no observations by US FDA on Telangana Unit-I facility
* Glenmark, US arm settle antitrust, consumer cases against 2 cholesterol drugs
* Tata Consumer in talks with group co Tata 1mg for distribution tie-up
* Zydus Lifesciences gets US FDA's final nod for Leuprolide Acetate injection

 

Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	29575.00	0.80	30035.00	28985.00
Alkem Laboratories	5700.00	(-)0.40	5784.30	5595.30
Aurobindo Pharma	1205.90	(-)1.40	1228.40	1186.80
Biocon	396.85	(-)3.50	404.80	391.00
Cipla	1511.80	(-)1.30	1534.80	1496.20
Divi's Laboratories	6373.00	(-)2.10	6503.30	6290.30
Dr Reddy's Laboratories	1243.90	(-)0.20	1257.50	1230.30
Gland Pharma	1809.70	(-)1.10	1852.00	1748.80
GlaxoSmithKline Pharmaceuticals	2497.90	0.80	2538.50	2467.70
Glenmark Pharmaceuticals	1844.20	(-)2.70	1933.40	1793.40
Granules India	544.20	(-)0.70	560.60	532.90
Ipca Laboratories	1444.00	(-)2.40	1470.70	1413.50
Laurus Labs	978.20	(-)2.10	1001.50	963.40
Lupin	2029.40	(-)1.30	2046.20	2012.80
Natco Pharma	864.80	6.40	880.80	849.00
Pfizer	5000.50	(-)1.50	5088.20	4904.20
Sanofi India	4512.80	(-)1.50	4620.50	4449.10
Sun Pharmaceutical Industries	1779.70	1.30	1794.00	1766.60
Torrent Pharmaceuticals	3686.50	(-)3.80	3747.20	3642.00
Zydus Lifesciences	924.30	(-)2.10	937.00	914.10
Nifty Pharma	22580.95	(-)1.10	22757.30	22456.80
Nifty 50	26068.15	0.60	26226.90	25972.90
S&P Bse Sensex	85231.92	0.80	85764.60	84921.50

 

End

 

Reported by P. Madhu Kumar

Edited by Akul Nishant Akhoury

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.